Summary The effect of nitric oxide-dependent vasodilators on vascular resistance of tumours and normal tissue was determined with the aim of modifying tumour blood flow for therapeutic benefit. Isolated preparations of the rat P22 tumour and normal rat hindlimb were perfused ex vivo. The effects on tissue vascular resistance of administration of sodium nitroprusside (SNP) and the diazeniumdiolate (or NONO-ate) vasodilators Constitutive and inducible isoforms of nitric oxide synthase (cNOS and iNOS respectively) have been detected in both experimental and human tumours (Buttery et al., 1993; Chhatwal et al., 1994; Cobbs et al., 1995; Thomsen et al., 1994 Thomsen et al., , 1995 . Competitive inhibition of NOS, using analogues of L-arginine at high doses, has been shown to decrease blood flow and energy status of experimental tumours and enhance the activity of bioreductive drugs (Andrade et al., 1992; Tozer et al., 1995; Wood et al., 1993, Correspondence: GM Tozer Received 2 April 1996; revised 11 July 1996; accepted 16 July 1996 1994). However, the capacity for EDRF production in tumours is unknown. Any difference from normal would provide a potential means of selectively modifying tumour blood flow for therapeutic benefit.
Selective pharmacological manipulation of tumour blood flow has potential for improving various therapeutic modalities. Many different classes of vasoactive agents have been tested in tumours and the results have been reviewed previously (Jain and Ward-Hartley, 1984; Sagar et al., 1993) .
Nitric oxide (NO) is well recognised as a primary determinant of normal tissue vasodilatory tone, but its role in the maintenance of vascular tone in tumours is poorly understood. Any differences in NO production or function in a tumour microenvironment would provide a means for selective tumour blood flow modification.
Various vasodilators, such as acetylcholine (ACh) and bradykinin, require an intact endothelium to dilate vascular smooth muscle. The requirement for release of an endothelium-derived relaxing factor (EDRF) to elicit AChinduced vasodilation was first demonstrated by Furchgott and Zawadzki (1980) . Nitric oxide (NO) is now recognised as the primary EDRF mediating vascular smooth muscle relaxation in normal tissues in response to endogenous vasodilators, such as ACh and bradykinin. The NO-donors, such as sodium nitroprusside (SNP) and the diazeniumdiolate (or NONOate) NOC-7, are endothelium independent. SNP is an ion-nitrosyl, which releases NO when it contacts biological tissue (Bates et al., 1991; Feelisch, 1991) . forms one of a group of compounds, which spontaneously release NO in aqueous solution (Maragos et al., 1993) , having a half-life of 10.1 min at physiological pH.
Constitutive and inducible isoforms of nitric oxide synthase (cNOS and iNOS respectively) have been detected in both experimental and human tumours (Buttery et al., 1993; Chhatwal et al., 1994; Cobbs et al., 1995; Thomsen et al., 1994 Thomsen et al., , 1995 . Competitive inhibition of NOS, using analogues of L-arginine at high doses, has been shown to decrease blood flow and energy status of experimental tumours and enhance the activity of bioreductive drugs (Andrade et al., 1992; Tozer et al., 1995; Wood et al., 1993, Correspondence: GM Tozer Received 2 April 1996; revised 11 July 1996; accepted 16 July 1996 1994). However, the capacity for EDRF production in tumours is unknown. Any difference from normal would provide a potential means of selectively modifying tumour blood flow for therapeutic benefit.
The aims of this study were (1) to determine the sensitivity of tumour vs normal tissue blood vessels to the vasodilatory effect of NO; and (2) to determine the capacity of tumour vs normal tissue endothelial cells for production of EDRF. To this end, isolated preparations of the rat P22 tumour and normal rat hindlimb were perfused ex vivo. The effects on vascular resistance of administration of the NO donors SNP and NOC-7 (endothelium-independent vasodilators) were compared with the effects of administration of ACh (an endothelium-dependent vasodilator) in tumour and normal tissue. Some of the results for tumour alone have appeared in preliminary form as part of conference proceedings .
Materials and methods Tumours
Early generations of the P22 transplanted rat carcinosarcoma were used for these experiments. Tissue-isolated tumours, whose vascular supply was derived solely from the superior epigastric vascular pedicle, were grown in the right inguinal fat pad of 10 to 11-week-old male BD9 rats. The method used was essentially as described previously (Tozer et al., 1994) , except that no attempt was made to physically enclose the growing tumour to prevent vessel ingrowth from surrounding normal tissue. Instead, the surgically prepared fat containing a small (approximately 1 mm3) piece of donor tumour was loosely sutured in position in the inguinal cleft in order to prevent twisting of the vascular pedicle but allow movement of the growing tumour within the cleft. This technique results in a lower incidence of inflammation than that resulting from enclosure of the growing tumour in silicon [as used previously (Tozer et al., 1994) ], while retaining a capacity for preventing vessel ingrowth from surrounding normal tissue. Tumours were used for experimentation when their vascular supply was seen to derive solely from the 1956 epigastric vascular pedicle (approximately 50% of preparations). Tumours were used after 2-3 weeks growth when they weighed 0.8-2.9 g.
Ex vivo perfusions
The method for ex vivo perfusion of tumours has been described in detail elsewhere (Tozer et al., 1994 . Normal tissues were not investigated in this former study. Therefore, all preparations in the present study, including the hindlimb preparations, were preconstricted with phenylephrine (PE, 1 -10 ,UM) or potassium chloride (KCI, 15-25 mM) by constant infusion into the afferent perfusate line. This infusion was continued throughout the time course of the experiment. Doses of PE/KC1 were adjusted in each preparation in order to achieve approximately equivalent increases in vascular resistance within the tumour and normal tissue groups. SNP and ACh were made up in physiological saline and administered to ex vivo perfused tumours or hindlimbs by constant infusion into the perfusate line at concentrations up to 100 /IM. (Alexis Corporation, Nottingham, UK) was made up in 2 mm sodium hydroxide (pH approximately 10) and administered, in concentrations up to 100 giM, by constant infusion to ex vivo perfused tumours only. Maximum concentration of sodium hydroxide after admixture to the perfusate was 100 gM, which had no effect on tumour The vasodilators, SNP and ACh, had no effect on vascular resistance of ex vivo perfused normal hindlimbs or tumours unless the baseline perfusion pressure was raised by administration of PE or KCI. This has been reported previously for tumours . Figure 1 and was observed in the present study for both PE and KCI, drugs which vasoconstrict via different mechanisms. Figure 2a shows an example of oscillations in perfusion pressure induced by KCI and the subsequent effect of SNP infusion. Since perfusate flow was kept constant, the oscillations directly represent changes in vascular resistance.
In this tumour, doses of 10 puM SNP and above vasodilated, as shown by the reduction in perfusion pressure. Generally, SNP was also observed to reduce the amplitude of oscillations and, in the specific case shown in Figure 2a , the oscillations disappeared at high SNP doses. Figure 2b shows a similar recording of PE-induced oscillations during ACh infusion. In this case, the oscillations only became apparent after the start of ACh infusion. Low doses of ACh had very little effect on mean perfusion pressure, but there was a small increase in perfusion pressure at 100 pM, the highest dose used. There is some indication in Figure 2b that the highest doses of ACh reduced the amplitude of oscillations, but this was generally less apparent than for SNP. Oscillatory changes in vascular resistance have also been reported for arteries supplying the P22 tumour growing in the inguinal fat pad (Kennovin et al., 1994) but, at present, there is no explanation for this effect. During the oscillatory phases, the mean perfusion pressure used for calculation of vascular resistance was determined from the mid-point between peaks and troughs in the recording.
Comparison of the effects of the vasodilators SNP and ACh on mean tumour vascular resistance is shown in Figure  3a and (Figure 3c ), but remained unchanged during ACh administration (Figure 3d ). The SNP result is consistent with a release of NO from SNP when it contacts biological material (Bates et al., 1991; Feelisch, 1991) and the observed tumour vasodilation (Figure 3a) . before constriction with PE/KCI. Significant differences from control are indicated by **(P<0.o001).
effect. SNP in aqueous solution had no effect on the nitrite assay at the doses used (results not shown). For ACh, no significant changes in nitrite concentration, at the 5% level, were observed at any dose used. Figure 4 shows that the NO-donor NOC-7 is also an effective dilator of tumour blood vessels. The decrease in vascular resistance was significant at 1 pm and above (P <0.001). A dose-response is suggested by a significant difference between vascular resistance measured at 0.1 gm compared with 1 and 10 gm NOC-7 (P <0.05). Comparison of Figures 3 and 4 shows that NOC-7 is more effective as a dilator of tumour blood vessels than SNP on an equimolar basis. This is consistent with a very efficient release of NO from NOC-7 and other diazeniumdiolates (Maragos et al., 1993 (Denekamp and Hobson, 1982) and their permeability (Dvorak et al., 1991) . Capacity for production of EDRF may represent a third difference, which could be exploited for selective chemical manipulation of tumour blood flow.
Muscarinic receptors for ACh exist on vascular smooth muscle cells as well as on endothelial cells. In the presence of an intact, functional endothelium, the overwhelming response to exogenously administered ACh is vasodilation resulting from release of EDRF following muscarinic receptor activation of the endothelium. However, in the case of an incomplete or dysfunctional endothelium, activation of receptors on vascular smooth muscle can dominate and result in vasoconstriction (Ralevic and Burnstock, 1993) . This phenomenon would explain the vasoconstrictive effect of ACh in our tumours.
There are many processes along the pathway for EDRF production following ACh administration, which could be deficient in tumours. It is not known, for instance, whether tumour endothelial cells lack muscarinic receptors or whether there is a deficiency in the enzyme biochemistry of cNOS. Using immunohistochemistry, cNOS has been identified in some human tumours (Cobbs et al., 1995; Thomsen et al., 1994 Thomsen et al., , 1995 , but not in some other tumour systems (Buttery et al., 1993) . However, it is not known whether any of these tumours are capable of EDRF production following receptor activation of the endothelium. In some vascular beds, part of the ACh-induced vasodilation appears to unrelated to NO (Zygmunt et al., 1994) , such that part of the tumour deficiency noted here may be the same. For example, a component of ACh-induced vasodilation has been attributed to prostacyclin, an NO-independent hyperpolarising factor or carbon monoxide formed from haemoxygenase (Poston and Taylor, 1995) .
A deficient vasodilatory response to ACh has also been reported for isolated arteries/arterioles from diabetic rats perfused ex vivo. Poston and Taylor (1995) have discussed possible artefacts in the systems used for these studies but conclude that the balance of the evidence is for a compromised capacity of the endothelium to relax the adjacent vascular smooth muscle in diabetes. Currently, there are no other investigations of EDRF activity in ex vivo perfused tumours for comparison with our results. The PE/KC1 induced oscillations in vascular resistance of our perfused tumours may represent a perfusion artefact, indicative of vascular damage, which could be the cause of the anomalous response of the tumour vasculature to ACh. It is known, for instance, that endothelial cell function is particularly sensitive to damage from ischaemia followed by reperfusion (Sternbergh et al., 1992) , which could occur during the surgical procedure. However, such an explanation would require that the tumour preparations were more prone to this type of injury than normal hindlimb preparations, which also underwent surgery but did vasodilate in response to ACh. The fact that SNP reduced the amplitude of oscillations observed in the tumour perfusions suggests that the oscillations resulted from interference with NO production in some way, which was counteracted by NO released from SNP. Both KCl and PE induced oscillations in tumour vascular resistance. KCl vasoconstricts via direct depolarisation of the vascular smooth muscle cell membrane, which causes activation of voltage-gated calcium channels (VGCs) and a consequent rise in intracellular calcium. PE vasoconstricts via x-adrenergic receptor activation on vascular smooth muscle cells, which results in an increase in free intracellular calcium via membrane depolarisation and activation of VGCs, activation of receptor-operated calcium channels and G-protein-mediated activation of phospholipase C (Levick, 1992) . Therefore, there is a component of PEinduced vasoconstriction, which acts in the same way as KCl, but there are also major differences in the mode of action of the two vasoconstrictors. Futher experiments with different vasoconstrictors would be required to determine whether it is the mechanism of vasoconstriction or the consequent increase in perfusion pressure that induces the oscillatory behaviour in the tumour preparations. Whatever the cause, the oscillations highlight some difference between tumour and normal tissue vasculature, which warrants futher investigation and could be exploited.
Currently, we are testing the in vivo response of the P22 tumour to the vasodilatory drugs tested here. If a defect in tumour EDRF production is established in vivo, it suggests a strategy for selective tumour blood flow modification. Vasodilators, such as hydralazine, can cause vascular shutdown in tumours, which potentiates the cytotoxicity of bioreductive drugs (Chaplin, 1989; Chaplin and Acker, 1987) . This is presumably a result of hypotension combined with minimal dilation of tumour blood vessels which appear to be maximally dilated under in vivo conditions (Peterson, 1991) . However, mean arterial blood pressure needs to be reduced below clinically feasible levels to obtain this effect (Horsman et al., 1992) . It is conceivable that, if ACh (or a related compound) induces tumour vasoconstriction in vivo, then a significant reduction in tumour blood flow could be obtained at moderate levels of hypotension. This strategy warrants investigation.
